Clinical trial
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of…
NCT00500058 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00500058 |
|---|---|
| Title | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 |
| Official title | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma" |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | SB-485232, Rituximab |
| Enrollment | 24 |
| Start date | Jul 31, 2007 |
| Primary completion | Mar 4, 2010 |
| Completion | Mar 4, 2010 |
| First posted | Jul 12, 2007 |
| Last update posted | Jul 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: